Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management

@article{Bichakjian2007MerkelCC,
  title={Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management},
  author={Christopher K. Bichakjian and Lori Lowe and Christopher D. Lao and Howard M. Sandler and Carol R Bradford and Timothy M. Johnson and Sandra Lynn Wong},
  journal={Cancer},
  year={2007},
  volume={110}
}
Merkel cell carcinoma (MCC) is a relatively rare cutaneous malignancy that occurs predominantly in the older white population. The incidence of MCC appears to have tripled during the past 20 years; an increase that is likely to continue because of the growing number of older Americans. The pathogenesis of MCC remains largely unknown. However, ultraviolet radiation and immunosuppression are likely to play a significant pathogenetic role. Many questions currently remain unanswered regarding the… Expand
Merkel cell carcinoma: An update and review: Current and future therapy.
TLDR
Because of the complexity, aggressive nature, and individuality of each case, MCC is best treated by a multidisciplinary team. Expand
Merkel cell carcinoma: An algorithm for multidisciplinary management and decision-making.
TLDR
This review aims to improve multidisciplinary decision-making by presenting scientific evidence of the contributions of each team member implicated in MCC management, and proposes a multidis disciplinary decision algorithm for managing this tumor. Expand
Merkel Cell Carcinoma of the Head and Neck: Challenges in Diagnosis and Therapy
  • B. Miles
  • Medicine
  • Journal of skin cancer
  • 2013
TLDR
Current clinical questions regarding the optimal management of MCC include surgical challenges such as histologic diagnosis, sentinel lymph node biopsy, and margin control, as well as issues related to reconstruction, and future areas of research will be identified to allow the reader to plot the trajectory of this disease's trajectory. Expand
Merkel cell carcinoma: a review of current advances.
TLDR
The recent advancement in diagnosis, discoveries in pathogenesis, and updates in management of Merkel cell carcinoma are reviewed; the acronym, AEIOU, has been proposed to aid in clinical identification. Expand
Questions in the Management of Stage I – III Merkel Cell Carcinoma
Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimalExpand
Merkel Cell Carcinoma
TLDR
Most published data support the use of a multimodality approach centered around surgical excision with negative margins, sentinel lymph node biopsy to establish the presence or absence of nodal metastases, adjuvant radiothearpy to decrease the risk of recurrence, and systemic chemotherapy in the case of widespread disease. Expand
Unanswered questions in the management of stage I-III Merkel cell carcinoma.
TLDR
This review addresses current uncertainty surrounding optimal management of Merkel cell carcinoma and highlights clinically relevant questions that further studies could address to improve the standard of care for MCC. Expand
Latest update on the clinical features and management of Merkel cell carcinoma.
TLDR
The most salient and clinically relevant updates of MCC since its first publication in July 2007, along with the new staging system established in 2009 after an extensive literature review, and an analysis of over 5,000 patients using the National Cancer Database has been included in this article. Expand
Merkel cell carcinoma from 2008 to 2012: reaching a new level of understanding.
TLDR
Patients continue to have distant failure because, currently, there is no effective systemic treatment available, and there remain controversies about its appropriate management. Expand
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs.
TLDR
Patients with advanced disease are encouraged to participate in clinical trials for treatment, indicating the largely unmet need for durable, safe treatment within this population. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 114 REFERENCES
Multimodality Treatment of Merkel Cell Carcinoma: Case Series and Literature Review of 1024 Cases
TLDR
Surgery and adjuvant radiotherapy appear to provide optimal local control in Merkel cell carcinoma, an aggressive cancer, with a high tendency for local recurrence and distant spread. Expand
Surgical management of Merkel cell carcinoma.
TLDR
The prognosis for patients with MCC is favorable, and even after recurrence the majority of patients experience long-term survival, and incorporation of size into the staging system more accurately predicts survival in patients with stage I disease. Expand
‘Leukaemic’ presentation of metastatic Merkel cell carcinoma
TLDR
To the authors' knowledge, there has been no previous published report of a ‘leukaemic’ presentation of MCC (it is unclear whether circulating MCC cells were present in the patient reported by Morris et al, 2005); limited experience with this rare entity suggests that such a presentation may not be uncommon. Expand
Clinical management and treatment outcomes of Merkel cell carcinoma.
TLDR
Local excision together with regional lymph node clearance as indicated, combined with adjuvant radiation treatment was associated with an improved survival, and the role of chemotherapy remains unclear. Expand
Early aggressive treatment for Merkel cell carcinoma improves outcome.
TLDR
It is suggested that early aggressive treatment for MCC improves both tumor control and survival, whereas the early use of chemotherapy does not improve outcome. Expand
Multimodality management of Merkel cell carcinoma.
TLDR
Merkel cell carcinoma is an aggressive dermal cancer with frequent nodal metastases; truncal tumors have the worst prognosis, but remission is possible with multimodality therapy. Expand
Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival.
TLDR
Cell size, mitotic rate, and tumor size are significant factors in relation to the biologic behavior of MCC. Expand
Merkel cell carcinoma: prognosis and treatment of patients from a single institution.
TLDR
The data demonstrate that the natural history of MCC is variable and dependent on the stage of disease at presentation, and pathologic nodal staging identifies a group of patients with excellent long-term survival. Expand
Merkel cell carcinoma.
Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab
TLDR
The development of MCC in a 51-year-old woman who presented with a red lump on the right cheek diagnosed as MCC may suggest that this complication rarely observed in CLL patients may have a link with strongly immunosuppressive therapy with 2-CdA and rituximab. Expand
...
1
2
3
4
5
...